FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

VC: Ambrx lands $52M in funds



Ambrx lands $52M in funds

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Ambrx
San Diego, CA

$52M
Third

Apposite

Ambrx is developing biopharmaceuticals based on protein modification.

Alder Biopharmaceuticals
Bothell, WA

$16M
Second

H.I.G. Ventures

Alder is advancing its antibody therapeutics program.

Ocera Therapeutics
San Diego, CA

$12M
Second

Sofinnova Ventures

Ocera is developing a product to fight Crohn's Disease.

IVREA Pharmaceuticals
Concord, MA

$11M
Unspecified

Atlas Venture, Easton Capital, CHL Medical Partners

IVREA, which focuses is dermatology, is using the funds for clinical development.


More stories about sofinnova ventures   Clinical Development   Venture Capital   Crohn's disease   Atlas Venture